DBV Technologies
29 rue du Faubourg
Saint Jacques
Paris
75014
France
Tel: 33-0-1-55-389270
Fax: 33-0-1-41-312882
Website: http://www.dbv-technologies.com/
Email: info@dbv-technologies.com
174 articles with DBV Technologies
-
DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments
8/2/2021
DBV Technologies S.A., a clinical-stage biopharmaceutical company, reported financial results for the second quarter of 2021.
-
DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021
7/26/2021
DBV Technologies, a clinical-stage biopharmaceutical company, announced that the Company will host a conference call and live audio webcast on Monday, August 2, 2021, at 5:00 p.m. ET to report first half 2021 financial results and provide a corporate update.
-
DBV Technologies to Present at Upcoming Investor Conferences - June 02, 2021
6/2/2021
DBV Technologies, a clinical-stage biopharmaceutical company, announced that Daniel Tassé, Chief Executive Officer, will participate in upcoming virtual investor conferences in June.
-
DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors
5/19/2021
DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting andthe Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors
-
DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021
5/5/2021
DBV Technologies, a clinical-stage biopharmaceutical company, announced the filing of its first Form 10-Q for the quarter ended March 31, 2021 with the U.S. Securities and Exchange Commission.
-
DBV Technologies Reports Q1 2021 Financial Results
5/3/2021
DBV Technologies S.A.DBV Technologies S.A.DBV Technologies S.A.DBV Technologies S.A., a clinical-stage biopharmaceutical company, reported financial results for the first quarter of 2021.
-
DBV announced official restructuring plan for keeping the company afloat.
-
DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.
-
In its CRL, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications.
-
DBV Technologies, located just outside Paris, announced it is cutting jobs while it awaits news from the U.S. Food and Drug Administration (FDA) about its application for Viaskin Peanut.
-
BioSpace takes a quick look at some recent, key industry news that is not related to the coronavirus.
-
Clinical Catch-Up: January 6-10, 2020
1/13/2020
The first full business week of the new year began with plenty of clinical trial news. Here’s a look. -
DBV announced positive topline results from its Phase III PEPITES trial evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children aged 4 to 11 years.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
BioSpace Global Roundup, Oct. 10
10/10/2019
Companies from across the globe provide updates on their business and pipelines. -
The company withdrew its initial BLA in December after the FDA requested more information regarding manufacturing procedures and quality controls.
-
With the ever-rising concerns over the costs of various prescription medications, a report from consumer pharmaceutical watchdog group Institute for Clinical and Economic Review released a report questioning the potential pricing of two yet-to-be-approved peanut allergy treatments.
-
JAMA Study Shows Viaskin Peanut Offers Clinically Meaningful Desensitization to Peanut
2/23/2019
DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association
-
DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age
2/13/2019
DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age
-
DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
11/21/2018
Three oral presentations highlighted analyses from the PEPITES Phase III study